<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03561415</url>
  </required_header>
  <id_info>
    <org_study_id>204/17</org_study_id>
    <nct_id>NCT03561415</nct_id>
  </id_info>
  <brief_title>Universal Prophylaxis Versus Pre-emptive Therapy With Posaconazole Post-Lung Transplant</brief_title>
  <acronym>UPPRITE</acronym>
  <official_title>Universal Posaconazole Prophylaxis Versus Pre-emptive Posaconazole Therapy for Fungal Infection Management Post-lung Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayside Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayside Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will examine 2 ways of using the antifungal posaconazole to prevent invasive
      fungal disease and the precipitation of chronic rejection post lung transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung transplantation (LT) is an increasingly used treatment for end-stage respiratory
      disease. However, it is expensive, with hospital costs alone estimated at
      &gt;US$500,000/transplant. Fungal infection and chronic lung allograft dysfunction (CLAD) are
      the major complications of LT. They pose the greatest threat to long-term survival and are
      reported to occur in 12-50% of LT recipients and cause death in 21.7-82% of these.

      Fungal infections occur in 3 major forms in LT recipients, namely colonisation,
      trachea-bronchial disease and invasive (or end-organ) disease. Whilst invasive fungal disease
      (IFD) is associated with the highest mortality, colonisation poses the greatest clinical
      challenge. It is the most common manifestation, can progress to IFD and can precipitate CLAD.
      Antifungal prophylaxis is used to minimise the risks associated with colonisation.

      Two main antifungal prophylaxis strategies are used. Universal prophylaxis (UP) is defined as
      the administration of antifungal agents to all patients post-LT. Most centres use UP. A
      systematic review and meta-analysis showed neither Aspergillus colonisation nor invasive
      aspergillosis (IA) (the commonest fungal infection in LT recipients) were reduced by UP. Yet
      it caused side-effects in 29.6%.

      The pre-emptive strategy is defined as the administration of antifungal agents when a fungal
      pathogen (including in donor specimens) is detected or there is serological evidence of a
      fungal pathogen in the absence of IFD from a post-LT surveillance bronchoscopy or other
      clinical investigations (i.e. colonisation).Observational data suggest that a pre-emptive
      strategy has similar IA incidence rates but fewer adverse drug reactions (ADR) than UP
      (16.1%). It has been estimated that a pre-emptive strategy can reduce antifungal drug use by
      43%.

      No direct comparison of the efficacy, safety and cost of the two strategies has been
      performed to date. Thus, a randomised controlled trial (RCT) is needed to determine the
      optimal strategy to reduce the impact of fungal infection in LT recipients. However, before
      we embark on a definitive phase III RCT powered for clinical outcomes we will perform a pilot
      feasibility RCT to generate data and answer practical questions to better inform the design
      of the definitive phase III RCT powered for clinical outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of: screened that are eligible, eligible that are enrolled, lost to follow-up or are withdrawn from the trial, receive their allocated treatment throughout the trial participation and have missing data during trial data collection.</measure>
    <time_frame>2 years and 3 months</time_frame>
    <description>Feasibility outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of: at least one episode of fungal pneumonia, fungal tracheobronchitis, or bronchial anastomotic fungal infection; diagnosed as having CLAD or died regardless of cause</measure>
    <time_frame>2 years and 3 months</time_frame>
    <description>Efficacy outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fungal pneumonia, fungal tracheobronchitis, or bronchial anastomotic fungal infection rates</measure>
    <time_frame>2 years and 3 months</time_frame>
    <description>Efficacy outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLAD rates</measure>
    <time_frame>2 years and 3 months</time_frame>
    <description>Efficacy outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality rates</measure>
    <time_frame>2 years and 3 months</time_frame>
    <description>Efficacy outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fungal pneumonia, fungal tracheobronchitis, or bronchial anastomotic fungal infection-related mortality rates</measure>
    <time_frame>2 years and 3 months</time_frame>
    <description>Efficacy outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLAD-related mortality rates</measure>
    <time_frame>2 years and 3 months</time_frame>
    <description>Efficacy outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to development of fungal pneumonia, fungal tracheobronchitis, bronchial anastomotic fungal infection</measure>
    <time_frame>2 years and 3 months</time_frame>
    <description>Efficacy outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to diagnosis of CLAD</measure>
    <time_frame>2 years and 3 months</time_frame>
    <description>Efficacy outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs associated with allocated arm including number of hospital admissions</measure>
    <time_frame>2 years and 3 months</time_frame>
    <description>Efficacy outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL) using Short Form Survey (sf-36) to measure patient health</measure>
    <time_frame>2 years and 3 months</time_frame>
    <description>Efficacy outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute rejection rates</measure>
    <time_frame>2 years and 3 months</time_frame>
    <description>Safety outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Posaconazole adverse drug reaction (ADR) rates</measure>
    <time_frame>2 years and 3 months</time_frame>
    <description>Safety outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who discontinue posaconazole because of an ADR</measure>
    <time_frame>2 years and 3 months</time_frame>
    <description>Safety outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total duration on posaconazole</measure>
    <time_frame>2 years and 3 months</time_frame>
    <description>Safety outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Fungal Infection</condition>
  <arm_group>
    <arm_group_label>Universal posaconazole prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Universal posaconazole prophylaxis: All patients will start posaconazole modified release tablet (300mg daily ) between Day 4 and Day 14 post lung or heart-lung transplantation for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-emptive posaconazole therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-emptive posaconazole therapy: Posaconazole will be started if a fungal pathogen is identified or there is serological evidence of a fungal pathogen in the absence of any evidence of invasive fungal disease and given for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Universal Posaconazole Prophylaxis</intervention_name>
    <description>All patients assigned to this arm will start posaconazole between Day 4 and Day 14 post lung or heart-lung transplant for a minimum of 3 months.</description>
    <arm_group_label>Universal posaconazole prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pre-emptive Posaconazole Therapy</intervention_name>
    <description>Posaconazole will be started if a fungal pathogen is identified or there is serological evidence of a fungal pathogen in the absence of any evidence of invasive fungal disease for 3 months.</description>
    <arm_group_label>Pre-emptive posaconazole therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female aged â‰¥ 18 years

          2. Undergoing bilateral sequential lung transplant (BSLT) or heart-lung transplant (HLT)
             including re-do transplant

          3. Able to give written informed consent

          4. Able to understand and comply with all trial requirements

        Exclusion Criteria:

          1. Less than 18 years of age

          2. Scheduled to undergo a single-lung transplant (known risk factor for IFD)

          3. Scheduled to undergo multi-organ transplant, other than HLT

          4. Recipients who will not be followed up for 1-year post-transplant at one of the trial
             sites

          5. Isolation of a mould within the 12 months prior to screening

          6. Evidence of a mycetoma within the 12 months prior to screening

          7. Proven or probable IFD within the 12 months prior to screening

          8. Patients with moderate or severe liver disease as defined by aspartate
             aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 5 times the upper limit of
             normal (ULN)

          9. Any other severe condition which in the site investigator's judgement may interfere
             with the trial evaluations or severely affect the patients safety

         10. Previous inclusion in the trial

         11. Currently enrolled in an antifungal or other investigational drug trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Orla Morrissey</last_name>
    <role>Study Chair</role>
    <affiliation>The Alfred</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Orla Morrissey</last_name>
    <phone>+61 3 90762631</phone>
    <email>o.morrissey@alfred.org.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Greg Snell</last_name>
    <phone>+61 90762000</phone>
    <email>g.snell@alfred.org.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Debbie Marriott, MD</last_name>
    </contact>
    <investigator>
      <last_name>Debbie Marriott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Peter Hopkins, MD</last_name>
      <phone>+61 7 31394000</phone>
      <email>Peter.Hopkins@health.qld.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Chambers, MD</last_name>
      <phone>+61 7 31394000</phone>
      <email>Daniel.Chambers@health.qld.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Hopkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Chambers, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfred Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Orla Morrissey, MD, PhD</last_name>
      <phone>+61 3 90762000</phone>
      <email>o.morrissey@alfred.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Greg Snell, MD</last_name>
      <phone>+ 61 3 90762000</phone>
      <email>g.snell@alfred.org.au</email>
    </contact_backup>
    <investigator>
      <last_name>Orla Morrissey, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Greg Snell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Glen Westall, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 9, 2018</study_first_submitted>
  <study_first_submitted_qc>June 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2018</study_first_posted>
  <last_update_submitted>June 17, 2018</last_update_submitted>
  <last_update_submitted_qc>June 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung transplant, prophylaxis, pre-emptive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Mycoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Posaconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

